Aratana Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

KANSAS CITY, Kan., April 22, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will present at the Bank of America Merrill Lynch 2015 Health Care Conference to be held May 12-14, 2015, at the Encore at the Wynn in Las Vegas, NV. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:


Bank of America Merrill Lynch 2015 Health Care Conference

Date: 


Thursday, May 14, 2015

Time: 


12:40 p.m., PST

Location:


The Encore at the Wynn

Address:


3131 Las Vegas Blvd. South, Las Vegas, NV 89109

The presentation will be webcast live and remain available for 30 days following the presentation.  To access the webcast, please visit the investor relations section of the Aratana website at aratana.investorroom.com.

About Aratana Therapeutics    
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts:

For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1026    
For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.

print email rss